Repligen (RGEN) AI Stock Analysis

• Market Cap: $6.63B
• Dividend Yield: N/A
• Average Volume (3M): 907.33K
• Price to Earnings (P/E): 188.5
• Beta (1Y): 0.99
• Revenue Growth: 11.74%
• EPS Growth: N/A
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.49
• Shares Outstanding: 56,331,110
• 10 Day Avg. Volume: 1,036,554
• 30 Day Avg. Volume: 907,330
• PEG Ratio: -0.65
• Price to Book (P/B): 4.38
• Price to Sales (P/S): 12.48
• P/FCF Ratio: 98.13
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 9.02
• Enterprise Value/Gross Profit: 17.72
• Enterprise Value/Ebitda: 37.72
• 1Y Price Target: $188.00
• Price Target Upside: 59.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 1.99
• Revenue Forecast (FY): $827.18M

• Rating: 60 Neutral
• Price Target: $123.00 ▲(4.58% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is driven by improving fundamentals and a constructive earnings outlook with guided growth and margin expansion. These positives are held back by clearly bearish technicals and an extremely high P/E with no dividend support.

Positive Factors

Recurring consumables revenue

Repligen’s business model is anchored in consumables and single‑use components that are replaced during manufacturing campaigns. That annuity-like demand provides durable, repeatable revenue as customers scale biologics production, supporting predictable cash flow over a multi-quarter horizon.

Strong cash generation

The company generated meaningful operating and free cash flow in 2025, with FCF roughly 80% of net income. Reliable cash conversion supports reinvestment, M&A and balance sheet flexibility, and helps absorb near‑term volatility in margins or capex over the next several quarters.

Product innovation & cross‑sell

Recent launches (SoloVPE PLUS, ProConnex MixOne, new resins) and a stronger cross‑sell model increase wallet share at existing customers. This expands addressable spend per account and supports durable organic growth as installed bases drive recurring consumable and upgrade demand.

Negative Factors

Margins below prior peak

Although profitability recovered in 2025, margins remain far below the 2021–2022 peak. Sustained lower margins indicate structural pressure from mix, M&A/FX dilution and investment spend, meaning margin restoration could take multiple quarters and limit free cash flow upside.

Leverage and low ROE

A large equity base with moderate leverage has resulted in low returns on equity. ROE near 2.3% and a prior-year loss imply capital is not yet generating strong returns, constraining shareholder return potential until sustained margin and growth improvement lift profitability.

Gene‑therapy platform headwind

Management explicitly models a gene‑therapy customer slowdown that trims near‑term growth, notably in Filtration. As modality mix shifts and some customers pause scale‑ups, consumable demand and equipment upgrades can be delayed, reducing revenue durability over several quarters.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Repligen makes money primarily by selling bioprocessing products and related consumables to biopharmaceutical and life sciences customers, generating revenue as these products are used across development and commercial-scale manufacturing. A significant portion of its revenue is tied to recurring, repeat purchases of consumables and single-use components (e.g., filters, cartridges, flow paths, and other disposable parts) that are replaced regularly during manufacturing campaigns, supporting an annuity-like revenue profile when customers’ production volumes grow. The company also earns revenue from the sale of durable or semi-durable capital items and systems used in bioprocessing (such as filtration or process-monitoring instruments), with ongoing follow-on revenue as customers buy compatible consumables, accessories, and replacements over time. In addition, Repligen generates revenue by providing process analytics solutions that are integrated into customers’ manufacturing workflows, supporting continued demand for associated sensors/probes and related consumables. Overall earnings are influenced by biopharmaceutical customers’ R&D activity, clinical progression, and commercial manufacturing volumes, since higher utilization and scale-up typically drive higher consumable purchases. Specific partnership details: null.

Repligen Financial Statement Overview

Summary

Fundamentals are improving: 2025 returned to positive net income and maintained positive free cash flow with moderate leverage supported by a large equity base. Offsets are weaker profitability versus 2021–2022, less consistent recent revenue growth after the 2023 decline, and some softening/volatility in cash-flow efficiency.

Income Statement

Profitability has recovered in 2025 (annual) with positive net income ($48.9M) after a loss in 2024, but margins remain well below the stronger 2021–2022 period (net margin ~6.6% in 2025 vs ~19–23% in 2021–2022). Revenue growth is positive but modest recently (2025 +4.29%, 2024 ~flat) following a large decline in 2023, indicating a slower and less consistent growth trajectory. Note: 2025 gross profit and margin are shown as 0, which limits margin quality assessment for that year.

Balance Sheet

The balance sheet looks solid with a large equity base ($2.11B) supporting moderate leverage (debt-to-equity ~0.33 in 2025), though leverage has risen versus 2020–2022 levels. Returns on equity are currently low (~2.3% in 2025) and were negative in 2024, signaling that profitability hasn’t yet fully caught up with the capital base despite the improved earnings in 2025.

Cash Flow

Cash generation is healthy with positive operating cash flow ($117.4M) and free cash flow ($94.0M) in 2025, and cash conversion is decent (free cash flow about 80% of net income). However, free cash flow declined in 2025 (-11.8%) after improvement in 2024, and operating cash flow relative to net income weakened in 2025 versus 2024, suggesting some near-term volatility in cash efficiency.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	738.26M	634.44M	632.36M	801.54M	670.53M
Gross Profit	347.62M	274.64M	278.44M	455.71M	391.25M
EBITDA	164.30M	80.26M	145.32M	277.31M	203.27M
Net Income	48.89M	-25.51M	35.60M	185.96M	128.29M
Balance Sheet
Total Assets	2.95B	2.83B	2.83B	2.53B	2.36B
Cash, Cash Equivalents and Short-Term Investments	767.63M	757.36M	751.32M	623.76M	603.81M
Total Debt	689.95M	686.25M	711.80M	422.96M	366.05M
Total Liabilities	843.57M	856.95M	866.34M	620.90M	608.29M
Stockholders Equity	2.11B	1.97B	1.96B	1.91B	1.75B
Cash Flow
Free Cash Flow	93.90M	142.49M	74.93M	38.74M	47.74M
Operating Cash Flow	117.42M	175.39M	113.92M	172.08M	119.02M
Investing Cash Flow	-298.47M	-86.38M	-123.28M	-233.24M	-221.17M
Financing Cash Flow	-15.21M	-82.90M	248.96M	-13.34M	961.00K

Repligen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 117.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Negative. The current price of 117.61 is below the 20-day moving average (MA) of 124.28, below the 50-day MA of 142.02, and below the 200-day MA of 138.95, indicating a bearish trend. The MACD of -7.10 indicates Negative momentum. The RSI at 35.73 is Neutral, neither overbought nor oversold. The STOCH value of 34.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	68 Neutral	$4.06B	40.58	8.52%	―	11.49%	-2.89%
ATR	65 Neutral	$7.98B	20.41	14.67%	1.50%	2.50%	25.05%
STVN	63 Neutral	$4.14B	24.79	9.72%	0.29%	9.19%	23.06%
RGEN	60 Neutral	$6.63B	188.46	2.37%	―	11.74%	―
BLCO	60 Neutral	$5.73B	-16.79	-5.61%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TFX	47 Neutral	$4.73B	-6.01	-23.70%	1.11%	5.43%	-245.18%

Repligen Corporate Events

Repligen Appoints Martin Madaus as New Board Chair

On January 6, 2026, Repligen Corporation announced that its board has elected independent director Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026, succeeding Executive Chair Tony Hunt, who will retire from the board on that date after more than a decade of leadership and will remain an advisor to the company through March 2027. The transition underscores Repligen’s effort to maintain strong governance and continuity in its bioprocessing-focused strategy, with management highlighting Madaus’s 36 years of industry experience—including his tenure leading Millipore’s transformation into a life sciences leader—as a key asset expected to support Repligen’s next phase of growth while reassuring stakeholders about stability in its leadership and long-term direction.

The most recent analyst rating on (RGEN) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.